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ABSTRACT
Introduction: Breathlessness remains a highly
prevalent and distressing symptom for many patients
with progressive life-limiting illnesses. Evidence-based
interventions for chronic breathlessness are limited, and
there is an ongoing need for high-quality research into
developing management strategies for optimal palliation
of this complex symptom. Previous studies have
suggested that selective serotonin reuptake inhibitors
such as sertraline may have a role in reducing
breathlessness. This paper presents the protocol for a
large, adequately powered randomised study evaluating
the use of sertraline for chronic breathlessness in
people with progressive life-limiting illnesses.
Methods and analysis: A total of 240 participants
with modified Medical Research Council Dyspnoea
Scale breathlessness of level 2 or higher will be
randomised to receive either sertraline or placebo for
28 days in this multisite, double-blind study. The dose
will be titrated up every 3 days to a maximum of
100 mg daily. The primary outcome will be to compare
the efficacy of sertraline with placebo in relieving the
intensity of worst breathlessness as assessed by a
0–100 mm Visual Analogue Scale. A number of other
outcome measures and descriptors of breathlessness
as well as caregiver assessments will also be recorded
to ensure adequate analysis of participant
breathlessness and to allow an economic analysis to
be performed. Participants will also be given the option
of continuing blinded treatment until either study data
collection is complete or net benefit ceases.
Appropriate statistical analysis of primary and
secondary outcomes will be used to describe the
wealth of data obtained.
Ethics and dissemination: Ethics approval was
obtained at all participating sites. Results of the study
will be submitted for publication in peer-reviewed
journals and the key findings presented at national and
international conferences.
Trial registration number: ACTRN12610000464066.
INTRODUCTION
Increasing numbers of individuals are living
with multiple chronic conditions and high
symptom burdens. Internationally, policy-
makers are calling for therapies that focus on
promoting not just the quantity but quality
of life.1 2 Breathlessness is one of the most
Strengths and limitations of this study
▪ This is an adequately powered study to provide a
clinically meaningful outcome.
▪ To optimise the generalisability of the findings,
this multisite study will capture people from
across a spectrum of care settings, including
direct inpatient care, inpatient consultations,
clinic attendances and community care.
▪ This study builds on the experience of several
double-blind randomised controlled trials in
therapeutic interventions for breathlessness.
▪ This is a relatively long study for participants
from palliative care which may potentially influ-
ence completion rates independently of the
intervention.
▪ The study has no end point assessing potential
changes in function (eg, accelerometry) as a
result of the intervention.
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prevalent and distressing symptoms experienced by
people with progressive life-limiting illness and is
deﬁned as “a subjective experience of breathing discom-
fort that consists of qualitatively distinct sensations that
vary in intensity”.3 The understanding of the physio-
logical mechanisms as well as the interdependence of
psychological, emotional, behavioural and environmen-
tal factors inﬂuencing the individual’s experience of
breathlessness has increased in recent years.4 There is
an ongoing need for high-quality research into interven-
tions that may help ensure optimal palliation of this dis-
tressing symptom.5
Chronic breathlessness is deﬁned as persistent
breathlessness at rest, or on minimal exertion despite
optimal management of the underlying causes.6 7 It
affects 50–70% of people with advanced malignancy8 9
and an even higher proportion of those with end-stage
respiratory or cardiac failure.10 In the later phases of
progressive life-limiting illnesses breathlessness, unlike
most other symptoms, typically worsens11 12 and is a
greatly feared symptom.13 This poses particular chal-
lenges for clinicians involved in providing symptom
control and end of life care.
In spite of the prevalence and burden of breathless-
ness, management options are limited and the current
evidence-based supports use of non-pharmacological
interventions such as pulmonary rehabilitation and
mobility aids;14 15 oxygen therapy in those with evidence
of hypoxia16 17 and the potential of systemic, oral or par-
enteral morphine.6 18–21 The complex interplay between
physiological and psychosocial antecedents to the sub-
jective experience of breathlessness justiﬁes exploration
of novel pharmacotherapeutic interventions.22 23
Serotonin as a neurotransmitter is strongly implicated
in the control and regulation of respiratory physiology
in the central nervous system.24 Sertraline is a selective
serotonin reuptake inhibitor (SSRI) used widely as an
antidepressant and in generalised anxiety disorders. A
previously published literature review20 identiﬁed two
non-randomised pilot studies25 26 and a case series27
that report symptomatic beneﬁt from SSRIs when used
to manage chronic breathlessness in patients with
chronic obstructive pulmonary disease (COPD). Papp
et al25 report a subjective improvement in well-being in
six people with COPD, three of whom had a diagnosis
of either phobia or panic disorder by standard psychi-
atric interview. These observations are supported by
work by Smoller et al27 who reported a decrease in
breathlessness and a subjective improvement in exercise
tolerance in a case series of seven people treated with
sertraline 25–100 mg daily, three of whom met
Diagnostic and Statistical Manual of Mental Disorders IV
(DSM-IV) criteria for mood or anxiety disorders on
structured clinical interview. Similar effects were found
by Perna et al26 in a small study looking at the use of
citalopram for relief of breathlessness in six people,
none of whom had a history of mood or anxiety disor-
ders by DSM-IV criteria, reporting decreased breathing
discomfort. Additionally, some studies which have investi-
gated the use of SSRIs to manage anxiety and depres-
sion in the COPD population report that breathlessness
scores are improved by the concomitant administration
of these medications.28 29 These studies were small pilot
studies and therefore not amenable to meta-analysis,30
however these data suggest a potential role for SSRIs in
reducing the subjective sensation of breathlessness in
people with chronic breathlessness even in the absence
of anxiety or panic disorders.
This paper describes the protocol and presents the
rationale for an adequately powered, multisite, stratiﬁed,
block randomised, double-blind, parallel arm, placebo-
controlled, titrated dose study investigating the role that
sertraline has in the relief of chronic breathlessness.
This phase III study aims to improve the evidence base
for the pharmacological management of chronic breath-
lessness and forms part of a programme seeking to
explore the role of existing medications in symptom
control. This paper complies with the SPIRIT recom-
mendations31 32 for protocol reporting and has been
adapted for publication from the original complete
study protocol written by the Palliative Care Clinical
Studies Collaborative (PaCCSC).33 The study will report
against CONSORT guidelines.34 35
METHODS AND ANALYSIS
Study design
A placebo-controlled study was chosen because there is
no registered medication for the pharmacological treat-
ment of chronic breathlessness, and there is clinical
equipoise regarding the net beneﬁt of SSRIs in this clin-
ical setting.
A 20 participant phase II study was initially conducted
at one site to establish feasibility and acceptability of the
proposed phase III study and to estimate the variance
between the two groups. The phase II study was analysed
while maintaining blinding of investigators and partici-
pants. There were no protocol changes following recruit-
ment of these ﬁrst 20 participants. Consequently, the
phase III study proceeded to multisite recruitment,
retaining these participants as the study design and pro-
cedures are identical.
Following informed consent and eligibility, partici-
pants will be randomised to receive either a daily dose
of sertraline or matched placebo. The dose will be
titrated in the ﬁrst 7 days and continued for a total of
28 days (ﬁgure 1). If the participant perceives beneﬁt
from the intervention, they will be given the option of
continuing the blinded treatment in an extension phase
either until study data collection is complete or partici-
pants perceive that the net beneﬁt ceases.
Participants will have assessments at baseline day 0,
day 9 and day 29 (following primary end point comple-
tion on day 28) and day 35 (at the end of dose down-
ward titration 6 days after treatment dose cessation) if
the participant does not enter the extension phase.
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Regular telephone contact will also be made to assess
safety and compliance.
If a participant agrees to enter the extension treatment
phase of the study, they will receive fortnightly telephone
contacts and monthly visits from a member of the
research team. This will help to ensure ongoing, high-
quality data collection and encourage compliance with
the intervention. Additionally, all participants will receive
two fortnightly telephone calls following treatment cessa-
tion to collect data for the economic analysis and to con-
tinuously assess participant safety and adverse effects.
Collaborating organisations
This multisite study will be coordinated by the
Australian national PaCCSC and sponsored by Flinders
University, Adelaide, Australia. It will recruit partici-
pants from across Australia with the collaborating sites
indicated in box 1. Clinical teams involved include
respiratory medicine, cardiology, oncology, general
medicine and palliative care. This diversity of clinical
teams reﬂects the heterogeneity and pervasiveness of
breathlessness across multiple chronic, progressive
illnesses.
Figure 1 Study design diagram.
VAS, Visual Analogue Scale.
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Study objectives
The primary objective of the study is to compare the efﬁ-
cacy of sertraline with placebo in relieving the intensity
of worst breathlessness36 in the previous 12 hours as
assessed by a 0–100 mm Visual Analogue Scale (VAS).
Secondary objectives include:
▸ Assessment of participant and caregiver quality of life
and participant performance status.
▸ Assessment of the mastery subscale of the Chronic
Respiratory Questionnaire (CRQ) between groups.
▸ Documentation and comparison of the side effects
and frequency of side effects experienced in each arm.
▸ To determine which participants derive the greatest
beneﬁt from sertraline using data from baseline par-
ticipant characteristics.
▸ Assessment of frequency of occurrence of common
toxicities and adverse effects such as nausea and falls.
▸ Assessment of changes in anxiety and depression
scores over the study period.
▸ Assessment of net effect (beneﬁt vs harms).
▸ Economic analysis of the net effect of sertraline incre-
mental to usual care from participant-level data col-
lected on costs and effects.
Study population
Adults with breathlessness deﬁned as level 2 or higher
on the modiﬁed Medical Research Council (mMRC)
Dyspnoea Scale37 (table 1) despite optimal treatment of
the underlying causes of breathlessness will be
approached by study investigators.
Level 2 or higher breathlessness on this mMRC Scale
corresponds with moderate-to-severe breathlessness.38 In
addition to being over the age of 18 years and being
able to speak and read English the inclusion criteria are:
▸ Chronic breathlessness where the underlying causes
have been maximally treated conﬁrmed by a specialist
relevant to the potential participant’s most signiﬁcant
underlying cause. The diagnosis of chronic is made
once all identiﬁed reversible causes of breathlessness
are documented and optimally managed. There is no
minimum duration for this diagnosis.
▸ No changes in medication for management of breath-
lessness for 1 week, except ‘as needed’ medications.
▸ Estimated life expectancy of at least 2 months.
▸ Be able to complete the informed consent process
and consent to participate in the study.
Owing to the multiple possible reported adverse effects
associated with sertraline and other SSRIs, a number of
exclusion criteria will be applied:
▸ Previous adverse reaction to sertraline.
▸ Severe hepatic impairment deﬁned as Child-Pugh39
Class C or higher.
▸ Gastrointestinal bleeding within the previous
6 months.
▸ Plasma sodium of <128 mmol/L.
▸ Recent difﬁcult seizure control.
▸ Respiratory depression with a respiratory rate <8
breaths per minute or previous opioid-induced
respiratory failure.
▸ A respiratory or cardiac event in the previous week
(not including mild upper respiratory tract
infections).
▸ Pregnant or breast feeding.
▸ Depressive symptoms as deﬁned by Hospital Anxiety
and Depression (HADS)40 Subscale >16.
▸ Current treatment with medicines that increase the
risk of serotonin syndrome (box 2).
Recruitment and consent
Potentially eligible participants will be identiﬁed by their
treating clinicians and referred to the local research
team. Case identiﬁcation in relevant outpatient clinics
and inpatient services using case note review will be
undertaken, with permission to approach potentially eli-
gible participants given by the relevant case manager or
consultant.
Written informed consent to participate in this study
will follow a process of information exchange between
study staff, clinicians and potential participants and care-
givers. Participant information sheets will form the basis
Box 1 List of collaborating sites
▸ New South Wales
– Braeside Hospital, Prairiewood
– Calvary Mater Hospital, Newcastle
– Sacred Heart Health Service, Darlinghurst
– Calvary Healthcare, Kogarah
– Liverpool Hospital, Liverpool
▸ South Australia
– Southern Adelaide Palliative Services, Daw Park
– Lyell McEwin Hospital, Elizabeth Vale
▸ Victoria
– St Vincent’s Hospital, Melbourne
– Barwon Health, Geelong
– The Austin Hospital, Heidelberg
▸ Queensland
– St Vincent’s Private Hospital, Brisbane
– The Prince Charles Hospital, Chermside
Table 1 The modified Medical Research Council
Dyspnoea Scale37
Grade Description of breathlessness
0 I only get breathless with strenuous exercise.
1 I get short of breath when hurrying on level
ground or walking up a slight hill.
2 On level ground, I walk slower than people of the
same age because of breathlessness, or I have to
stop for breath when walking at my own pace on
the level.
3 I stop for breath after walking about 100 yards or
after a few minutes on level ground.
4 I am too breathless to leave the house or I am
breathless when dressing.
4 Watts GJ, et al. BMJ Open 2016;6:e013177. doi:10.1136/bmjopen-2016-013177
Open Access
group.bmj.com on May 7, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
of discussion, and the participant will be given as much
time as necessary to consider the study. Site coordinators
and research nurses at each involved site are trained in
the consent procedures for this study.
Any participant who consents to be included in the
study may also nominate their primary caregiver (or
person likely to provide care if they were to need care at
some time in the future) for involvement in the study.
The caregiver will be asked to consent to completion of
a caregiver-speciﬁc quality of life assessment to be
included in the study. Consent by caregivers to complete
this assessment will not affect participant eligibility.
Randomisation
At each site involved, on referral to the study, partici-
pants will be sequentially allocated a unique identifying
number to be used for all subsequent study documenta-
tion. This will ensure conﬁdentiality is maintained. The
randomisation request will be generated by the receipt
of a prescription of the study drugs by a clinical trial site
pharmacist. Randomisation will be stratiﬁed according
to a baseline measure of the anxiety and depression sub-
scales of the HADS.40 Initial stratiﬁcation will be into
two groups according to HADS anxiety subscale; 0–10
(normal to mild) or 11–21 (moderate to severe). Within
these two groups, participants will be further stratiﬁed
into two further groups categorised by HADS depression
subscale; 0–10 (normal to mild) or 11–16 (moderate).
This will create four strata (table 2).
Within each site and within each of the four strata,
randomisation will occur in blocks of four in a 1:1 ratio
to ensure even allocation.
Intervention
All participants will take one blinded opaque capsule
each morning on waking for 28 days. Participants and
investigators will be blinded to the medication provided.
As there is a theoretical concern that SSRIs can blunt
carbon dioxide sensitivity25 42 and because SSRIs are
rarely tolerated at full dose when initiated without titra-
tion, therapy will be initiated at low dose with titration
over 7 days. Those in the active arm will start oral sertra-
line 25 mg daily (ﬁgure 1). This dose will then double
every 3 days to reach a maximum dose of sertraline
100 mg daily by the beginning of day 7 if tolerated.
Those in the control arm will receive an identical
appearing dose of placebo titrated over the same period
of time. Low-dose oral morphine has demonstrated
beneﬁt over placebo for symptomatic relief of chronic
breathlessness,6 19 21 43 hence, all participants will be
prescribed immediate release morphine solution.
Participants will be permitted to take 2.5 mg of oral mor-
phine immediate release solution every 4 hours up to six
doses per day on an as needed basis. Docusate with
senna will also be prescribed to all participants for treat-
ment of opioid-induced constipation if required.
Participation in the study will cease if adverse effects
related to the study medicines develop and are
unacceptable to the participant or clinician in charge of
the participant’s care. Adverse effects will be classiﬁed
by National Cancer Institute Common Terminology
Criteria for Adverse Events, V.4 (NCI CTC AE v4),44
recorded and treated symptomatically. Anyone with NCI
CTC AE v4 scores of 3 not responding to symptomatic
treatment or scores of 4 or higher will be withdrawn
from the study. Other reasons for discontinuation of
study medicines are if treatment is deemed ineffective
by the treating clinician and an alternative therapy is
required, increasing breathlessness despite study medica-
tion and maximal use of rescue morphine solution.
Withdrawal of consent, hyponatraemia, falls and other
adverse events may also cause withdrawal from the study.
Reasons for withdrawal will be documented.
Box 2 Examples of medicines41 that increase the risk of
serotonin syndrome
Examples of medicines with increased risk of serotonin syndrome
Prescribed medications
▸ Selective serotonin reuptake inhibitors (SSRI)
– Citalopram, escitalopram, paroxetine, fluoxetine,
clomipramine
▸ Serotonin-norepinephrine reuptake inhibitors (SNRI)
– Venlafaxine
▸ Noradrenergic and specific serotonergic antidepressant
(NaSSA)
– Mirtazapine
▸ Tricyclic antidepressants (TCA)
– Amitriptyline
▸ Serotonin receptor agonists
– Buspirone, triptans
▸ Monoamine oxidase inhibitors (MAOI)
– Moclobemide (within 2 days of entry into study)
– Phenelzine, tranylcypromine (within 4 weeks of entry to
study)
▸ Amphetamine-type drugs
– Dexamphetamine, methylphenidate
▸ Weight-loss medication
– Phenteramine, diethylpropion, sibutramine
▸ Other prescription medications
– Lithium, carbamazepine, linezolid, imatinib
▸ Over-the-counter medication
– Dextromethorphan, chlorpheniramine, brompheniramine
Complementary therapies
– St John’s Wort, tryptophan, S-adenosyl-methionine
Table 2 Randomisation strata according to HADS
subscale scores40
Stratum
1
Stratum
2
Stratum
3
Stratum
4
HADS Anxiety
Subscale Score
0–10 11–21 0–10 11–21
HADS
Depression
Subscale Score
0–10 0–10 11–16 11–16
HADS, Hospital Anxiety and Depression Scale.
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Participants will be monitored for harms at days 3, 6
and 9. If adverse effects persist despite symptomatic
treatment, participants may continue to take part in the
study but will continue at the sertraline dose prior to
adverse symptoms being noted. If adverse effects are
noted at the starting dose of sertraline 25 mg, partici-
pants will be withdrawn from the study.
Assessment of net clinical beneﬁt will be conducted
on day 29 of the study by study nurses for the primary
outcome of worst breathlessness averaged over the last
three study days and the adverse effects of the interven-
tion that were speciﬁcally sought during the study. If
there is no clinical beneﬁt, dose will be tapered down by
halving the dose every 3 days to 25 mg and then
stopped. As previously mentioned, participants will have
the option of continuing the blinded treatment until
completion of study data collection or beneﬁt ceases.
Data collection and outcome measures
Current literature suggests that there may be two dis-
crete pathways involved in the sensation of breathless-
ness. O’Donnell et al suggest that a two-phase gating
model for breathlessness exists. A ﬁrst gate considers the
intensity of breathlessness; the second considers its
unpleasantness.45 Some studies suggest that people can
discriminate between these two pathways.11 46
Participants in this study will therefore be asked to rate
breathlessness intensity and unpleasantness using VAS
and Likert Scales (box 3).
Changes in breathlessness intensity will be measured
on a 100 mm VAS and 4-point Likert Scales (box 3).
Participants will be asked to complete a diary in the
morning and evening at baseline and on days 7, 14, 26,
27 and 28 (table 3), recording the intensity and unpleas-
antness of breathlessness using the two scales. The
primary outcome measure will be based on average
worst morning and evening breathlessness intensity
based on VAS scores on days 26, 27 and 28 of the inter-
vention period. A 15% improvement in breathlessness
score from baseline is considered a clinically meaningful
improvement, consistent with patient-deﬁned minimally
clinically important differences in VAS Scales.47
Secondary outcomes will be assessed by completion of
a number of validated participant and research team-
mediated measures at various time points throughout
the study period. Box 3 gives an overview of the ques-
tionnaires and scales used in this study, and table 3 pro-
vides an overview of the study timeline and the outcome
measures recorded at each time point. The range of
assessment tools will ensure quantitative and qualitative
assessment of participants’ symptom severity and ensure
measurement of quality of life for participants and care-
givers in line with Australian National Palliative Care
Strategy’s aims.48
Blood sampling will be required for laboratory assess-
ment of full blood count, electrolytes, liver and renal
function at eligibility. A sample will be taken at eligibility
assessment if no sample is available from the preceding
7 days. Child-Pugh scoring of hepatic dysfunction39 will
also occur at eligibility. Sertraline is known to cause
hyponatraemia so serum sodium levels will be monitored
weekly throughout the study.
Respiratory and cardiac function will be recorded
from recent spirometry and echocardiography testing if
available but are not essential for participation in this
study. Owing to the theoretical risk of respiratory depres-
sion, end-tidal carbon dioxide levels and pulse oximetry
will be measured at baseline and at study exit.
Demographics including age, gender, availability of
primary caregiver, postcode, ability to read and speak
English and Aboriginal or Torres Strait Islander status
will be recorded. In addition, main clinical diagnoses
will be detailed including the dominant aetiology of the
breathlessness, co-morbid illnesses and smoking history
recorded in pack years. The Charlson Comorbidity
Index (CCI) will be used as a uniform measure of
co-morbidity and tested as an independent predictor of
long-term survival.62 63
The participant diary will form an important source of
data collection. It is completed at baseline and on days 7,
14, 21 and on the past 3 days of intervention 26, 27 and
28 (table 3). It will be used to document and record:
▸ Breathlessness intensity and unpleasantness VAS and
Likert Scales.
▸ Current, average and worst breathlessness and relief
of breathlessness using VAS and Likert Scales.
▸ mMRC breathlessness scale measures functional
impairment due to breathlessness.37 52
▸ Symptoms associated with sertraline use using Likert
Scales.
▸ Well-being and global quality of life using numerical
rating scale.
▸ Record of ‘as needed’ medication usage.
Data will be collected on potential adverse effects of
sertraline including nausea; diarrhoea; tremor; agitation
and restlessness; sexual dysfunction and general well-
being. Adverse events are assessed according to Good
Clinical Practice (GCP) guidelines64 and recorded and
reported according to PaCCSC standard operating
procedures.
Data will also be collected from participants on the
use of hospital services, specialised palliative care ser-
vices, community nurses, local General Practitioner/
practice nurses and changes in medicines to inform the
economic analysis.
Sample size calculation
As previously mentioned, this is a phase III study that
incorporates a blinded analysis of 20 participants from a
single-site phase II study with an identical protocol. This
analysis was conducted and overseen by the Data Safety
Monitoring Committee. The blinded results were shared
with the study investigators to ensure feasibility, accept-
ability of the outcome measures and that the variance of
the primary outcome measure was within the anticipated
range. No changes were made to the phase III protocol
6 Watts GJ, et al. BMJ Open 2016;6:e013177. doi:10.1136/bmjopen-2016-013177
Open Access
group.bmj.com on May 7, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
as a result of this analysis. Using these data, 75 com-
pleted participants in each study group will provide
∼ 80% power at a two-tailed type 1 error of 0.05 to
detect a difference of 41% of participants in the sertra-
line group meeting the deﬁnition of response, versus
20% in the placebo group. The study needs to recruit 60
participants in each stratum randomised 1:1 between
intervention and control. Allowing for attrition, 240
people will be randomised to give 150 complete sets of
data.
Statistical analysis
The null hypothesis of the study is that there is no differ-
ence between the net clinical effects of sertraline and
placebo on the sensation of chronic breathlessness. As
previously detailed, response is deﬁned as at least 15%
improvement in breathlessness scores from baseline.
Analysis of the primary outcome will be through com-
parison of the percentages of participants achieving a
15% reduction in breathlessness from baseline in the
two study groups by χ2 testing without continuity
Box 3 Assessment methods and questionnaires used in this study
Intensity of breathlessness
▸ Visual Analogue Scale (VAS)
– 100 mm scale
– 0=‘no breathlessness at all’; 100=‘breathlessness as bad as you can imagine’
▸ Likert Scale
– 4-point scale: none, mild, moderate and severe
Unpleasantness of breathlessness
▸ VAS
– 100 mm scale
– 0=‘not unpleasant at all’; 100=‘the most unpleasant breathlessness I’ve ever felt’
▸ Likert Scale
– 4-point scale: none, mild, moderate, severe
Descriptors of breathlessness49–51
▸ Fifteen categorical descriptors presented to participants in random order
▸ Participants choose appropriate descriptors that characterise their breathlessness and indicate up to three most applicable statements
Modified Medical Research Council (mMRC) Dyspnoea Scale37 52
▸ 5-point (0–4) categorical breathlessness scale
▸ Descriptive measure of functional impairment due to breathlessness
▸ Lower scores imply less breathlessness
Chronic Respiratory Questionnaire (CRQ)—Dyspnoea Subscale53 54
▸ Total of 20 questions covering social and emotional symptoms and perceptions of breathlessness in relation to five activities over the pre-
ceding 2 weeks
▸ Higher scores imply better respiratory function
Global impression of change
▸ 7-point scale regarding participant perception of change since starting study
▸ From ‘very much worse’ to ‘very much improved’
▸ Adapted for measurement of breathlessness from original55
▸ Higher scores imply better global quality of life
Life space assessment56
▸ Yes or no responses to simple questions assessing mobility including where a person goes, frequency and dependency when mobilising
▸ Higher scores imply better mobility
Australia-modified Karnofsky Performance Status (AKPS)57
▸ Validated variant of Karnofsky performance status
▸ Scored 0–100 in increments of 10 assigned to participants based on ability to perform activities of daily living
▸ Higher scores imply better level of function
Hospital Anxiety and Depression Scale (HADS)40
▸ 14-item questionnaire consisting of two 7-item subscales looking at depression and anxiety, respectively
▸ Higher scores are associated with greater morbidity
Folstein Mini-Mental Status Examination (MMSE)58
▸ 11-task examination assessing higher cognitive function scored out of 30
▸ Higher scores suggest better executive functioning
EORTC QLQ-C15 (European Organization for Research and Treatment of Cancer—Quality of Life Questionnaire 15)
▸ 15-question subset of the original 30 question assessment of health-related quality of life59
▸ Higher scores suggest better quality of life
CQOLC (Caregiver Quality of Life Index)60
▸ Well-established quality of life assessment for caregivers of people with cancer61
▸ 35-item questionnaire assessing physical, social, emotional, financial aspects of well-being
▸ Higher scores suggest better quality of life
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Table 3 Table of study measures according to time point and timeline
Dose up-titration and core study period
Dose
down-titration Ongoing treatment phase Follow-up
Time point −1 0 and 1 2 3, 4, 5 6 7 8 1 2 3 4 5 6
Assessment type
Eligibility
Baseline T/C Visit T/C Visit T/C Visit Treatment
cessation
T/C Visit T/C Visit T/C Visit Fortnightly
for 4 weeksTimeline day 0 3 and 6 9 14, 21, 25 29* End+3 End+6 42 56 70 84 98 112
Research team mediated assessments
Vital signs ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Bloods: FBC, Elec, CC ✓
Child-Pugh ✓
Pulse oximetry ✓ ✓ ✓ ✓ ✓ ✓
Spirometry ✓ ✓ ✓
Echocardiography ✓ ✓ ✓
Serum sodium ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
End-tidal CO2 ✓ ✓ ✓ ✓ ✓ ✓
Demographics ✓ ✓
Medical and physical
examination
✓
Clinical history ✓
CCI ✓
AKPS ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Safety and AE ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Drug compliance ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Global impression of
change
✓ ✓
Desire to continue
therapy
✓ ✓
Economic analysis data ✓ ✓
Diary reminder ✓ ✓ ✓
Participant mediated assessments
MMSE ✓
Descriptors of
breathlessness
✓ ✓ ✓
mMRC Breathlessness
Scale
✓
CRQ-Breathlessness
Scale
✓ ✓ ✓ ✓ ✓ ✓ ✓
EORTC QLQ-C15 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
CQOLC ✓ ✓ ✓
HADS ✓ ✓ ✓ ✓
Life space assessment ✓ ✓ ✓ ✓
Continued
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correction. Secondary analysis will be through longitu-
dinal repeated measures mixed models with unstruc-
tured covariance matrices assessing group by time and
group by intervention effects across the entire study
period with particular focus on the past 3 days to
compare each arm. This approach will be applied for
breathlessness and Quality of Life (QOL) assessments,
as well as main anticipated adverse effects.
Multivariable regression models will be used to estab-
lish clinically relevant baseline predictors of response
(percent reduction over baseline breathlessness) explor-
ing baseline breathlessness, baseline gas exchange,
CCI,62 HADS scores40 including depression and anxiety
subscores and functional status.
Secondary outcomes such as caregiver well-being,
changes in functional status using Australian modiﬁed
Karnofsky Performance Status (AKPS)57 (primarily as a
safety measure) and utility associated with health quality
of life between the placebo group and the sertraline
group will be examined using Mann-Whitney U tests.
This same statistical method will also be used to
compare adverse effects between study arms. Missing
data for primary and secondary end points will be dealt
with by multiple imputations.
Economic evaluation
The main objective of the economic evaluation is to esti-
mate the incremental costs, effects and cost-effectiveness
of sertraline relative to placebo for the palliative relief of
breathlessness in people with chronic breathlessness. A
within-trial cost-effectiveness analysis will be undertaken
from a healthcare provider perspective using participant-
level data collected from randomisation up to 28 days
after completing the study intervention or death, which-
ever occurs sooner. Mean costs and effectiveness will be
estimated for the sertraline and placebo arms including:
sensation of breathlessness, quality of life, caregiver
quality of life, intervention costs, hospitalisations, com-
munity support and other medications controlling for
baseline use. Resource use will be costed according to
the Australian Manual of Resource Items and their
Associated Costs65 in Australian dollars. Incremental net
monetary beneﬁt (INMB) and cost-effectiveness accept-
ability curves (CEACs) will be estimated at potential
threshold values for: (1) a 1% reduction in breathless-
ness and (2) one extra responder (response is deﬁned as
at least 15% improvement in breathlessness scores from
baseline). INMB is the monetary value of additional
effects of care minus the additional costs of care.66
CEACs graphically represent the probability of a positive
INMB over plausible threshold values for the outcome of
interest. The threshold value indicates the decision-
maker’s maximum acceptable monetary value for 1 unit
gain of effect.66 67 Bootstrapping on participants’ costs
and effects across 5000 replicates will be used to assess
the uncertainty for costs, effects and cost-effectiveness,
and 95% CIs will be calculated for the INMB and CEACs
using these replicates.68
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Ethical considerations
In order to maximise the collection of valuable data
while minimising patient burden, only outcome mea-
sures previously validated in this patient population will
be collected. Invasive measures have been minimised to
cause the least possible physical stress. It is recognised
that completion of written study measures can be a sig-
niﬁcant source of stress and burden to the population
who will participate in this study. Sensitive issues regard-
ing the measurement of functional status can be con-
fronting for participants and discussing quality of life
and other questions may also cause psychological dis-
tress. As such, any emotional distress caused by the study
would prompt intervention and support from the spe-
cialist palliative care team who would be involved in the
care of the people participating in this study. The
research team will always be attuned to monitoring for
signs of participant distress, and ongoing training will be
provided to the research teams in conjunction with GCP
principles.64
Consent to participate will be obtained by a research
team member not involved in the participant’s usual
clinical care. This will also assist with the separation of
research and clinical responsibilities of the clinical staff.
Everyone has the ability to decline to participate in the
study, and participants can withdraw at any time without
detriment to the provision or quality of their clinical
care.
The protocol has been initially reviewed and approved
by the Cancer Institute New South Wales (CI NSW),
Human Research Ethics Committee (HREC), New
South Wales in 2010 (approval number 2010C/02/120)
but was transferred to the Prince of Wales Hospital
HREC in 2013 (approval number 13/327HREC/13/
POWH/785) following closure of the CI NSW HREC.
Each individual collaborating site has also each obtained
relevant HREC approvals to recruit to this study.
Confidentiality
Data will be retained in accordance with the principles
of GCP.64 Participants will be allocated a unique identiﬁ-
cation (ID) number at entry. The master list linking par-
ticipant personal information and ID number will be
maintained in a separate locked cabinet and password-
protected hard drive. Data will be analysed by ID
number only. Records will be retained for 15 years after
study completion and then destroyed in accordance with
PaCCSC standard operating procedures consistent with
current HREC requirements.
Dissemination
The results of this trial will be submitted for publication
in peer-reviewed publications and the key ﬁndings pre-
sented at national and international conferences. If the
study shows a net beneﬁt, contact will also be made with
key professional groups, and regulatory and funding
bodies.
DISCUSSION
This study protocol represents a large, randomised study
evaluating a non-opioid pharmacological intervention
for chronic breathlessness in people with progressive life-
limiting illnesses. Chronic breathlessness is one of the
most feared symptoms and the potential implications for
quality of life are substantial if effective treatment can be
found. Currently, there is no medicine registered inter-
nationally for the treatment of chronic breathlessness
despite its prevalence. This study will evaluate a new, but
theoretically useful therapy by quantifying net clinical
effect as well as assessing cost-efﬁcacy to inform clini-
cians, policymakers and patients.
The recently published randomised controlled trial
investigating the use of the azapirone serotonergic
anxiolytic buspirone 20 mg daily in the management of
cancer-related breathlessness is an example of the high-
quality studies that are now being undertaken. This
large, multicentre phase II trial failed to show improve-
ment in breathlessness as measured by the Oxygen Cost
Diagram or anxiety, measured by the Spielberger
State-Trait Anxiety Inventory, after 6 weeks of interven-
tion.23 This study protocol continues the theme of inves-
tigating the potential uses of non-sedating anxiolytics in
the management of breathlessness and builds on previ-
ous work by using a different medicine with careful dose
titration in a larger and more diverse participant popula-
tion for a longer follow-up period.
With the exception of buspirone, developing the evi-
dence base to date has focused on morphine for the
treatment of chronic breathlessness. Although the
balance of evidence favours symptomatic beneﬁt safety,
many practitioners are still concerned about the poten-
tially rare but catastrophic problem of respiratory
depression when using opioids. The largest trials to date
have sought to further minimise any risk by using
regular, low dose oral extended release morphine to
minimise peak drug concentrations.6 19 43
Recruitment to randomised controlled palliative care
studies is challenging but feasible if it is approached sys-
tematically.69 70 PaCCSC has a strong track record of suc-
cessfully designing and conducting phase III studies in
this patient population,71–73 making this the world’s
largest palliative care clinical trial group having rando-
mised more than 1700 participants to phase III studies.
The key to the anticipated success of this study is that it
is being conducted across multiple sites which will allow
adequate and timely recruitment. The trial began enrol-
ling participants in January 2011 and as of April 2016
has randomised 192 participants with a projected
recruitment completion date of March 2017. In add-
ition, this protocol has been adapted by a group in the
UK investigating the effect of mirtazapine in the man-
agement of chronic breathlessness in a similar group of
participants.74
The economic analysis will aid evidence-based
decision-making in palliative care service provision and
inform any subsequent regulatory or funding body
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applications by providing prospectively collected, and
jointly considered data on health resource use and costs
in the clinical setting of palliating chronic
breathlessness.
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